{"id":"sodium-succinate","rwe":[{"pmid":"41863717","year":"2026","title":"Pharmacodynamic evaluation and mechanism study of cord blood nucleated cell extract in the treatment of rheumatoid arthritis.","finding":"","journal":"Clinical rheumatology","studyType":"Clinical Study"},{"pmid":"41863694","year":"2026","title":"Nitrogen metabolic characteristics and adaptive mechanisms of Paracoccus sp. QD-21 under complex nitrogenous environments.","finding":"","journal":"Biodegradation","studyType":"Clinical Study"},{"pmid":"41836248","year":"2026","title":"Nanoparticle albumin-bound paclitaxel -induced severe interstitial lung disease in a gastric cancer patient: a case report.","finding":"","journal":"Frontiers in oncology","studyType":"Clinical Study"},{"pmid":"41824819","year":"2026","title":"Impact of acupuncture combined with ganglioside therapy on serum inflammatory cytokine levels in acute cervical spinal cord injury without fracture or dislocation.","finding":"","journal":"Medicine","studyType":"Clinical Study"},{"pmid":"41824219","year":"2026","title":"Clinical characteristics and diagnostic indicators of childhood-onset systemic lupus erythematosus complicated with macrophage activation syndrome.","finding":"","journal":"Clinical rheumatology","studyType":"Clinical Study"}],"_fda":{"id":"7700d2a0-e17c-49e4-96ea-956742ed0e70","set_id":"05d95a56-b03a-4d5b-9877-2853ac470fa1","openfda":{"unii":["LEC9GKY20K"],"route":["INTRAMUSCULAR","INTRAVENOUS"],"rxcui":["311659","1743704"],"spl_id":["7700d2a0-e17c-49e4-96ea-956742ed0e70"],"brand_name":["Methylprednisolone Sodium Succinate"],"spl_set_id":["05d95a56-b03a-4d5b-9877-2853ac470fa1"],"package_ndc":["0143-9754-01","0143-9754-25","0143-9753-25"],"product_ndc":["0143-9753","0143-9754"],"generic_name":["METHYLPREDNISOLONE SODIUM SUCCINATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["METHYLPREDNISOLONE SODIUM SUCCINATE"],"manufacturer_name":["Hikma Pharmaceuticals USA Inc."],"application_number":["ANDA203125"],"is_original_packager":[true]},"version":"4","warnings":["WARNINGS Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. General Reconstituted methylprednisolone sodium succinate sterile powder contains benzyl alcohol, which is potentially toxic when administered locally to neural tissue . Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources (see PRECAUTIONS, Pediatric Use ). Injection of methylprednisolone sodium succinate may result in dermal and/or subdermal changes forming depressions in the skin at the injection site. In order to minimize the incidence of dermal and subdermal atrophy, care must be exercised not to exceed recommended doses in injections. Injection into the deltoid muscle should be avoided because of a high incidence of subcutaneous atrophy. Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy (see ADVERSE REACTIONS ). In patients receiving the 40 mg presentation of methylprednisolone sodium succinate for injection during the treatment for acute allergic conditions and where these symptoms worsen or any new allergic symptoms occur, consideration should be given to the potential for hypersensitivity reactions to cow’s milk ingredients (see CONTRAINDICATIONS ). If appropriate, administration of methylprednisolone sodium succinate for injection should be stopped, and the patient’s condition should be treated accordingly. Alternative treatments, including the use of corticosteroid formulations that do not contain ingredients produced from cow’s milk, should be considered for acute allergy management, where appropriate. Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy who are subjected to any unusual stress before, during, and after the stressful situation. Results from one multicenter, randomized, placebo-controlled study with methylprednisolone hemisuccinate, an intravenous corticosteroid, showed an increase in early (at 2 weeks) and late (at 6 months) mortality in patients with cranial trauma who were determined not to have other clear indications for corticosteroid treatment. High doses of systemic corticosteroids, including methylprednisolone sodium succinate, should not be used for the treatment of traumatic brain injury. Cardio-renal Average and large doses of corticosteroids can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Literature reports suggest an apparent association between the use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see CONTRAINDICATIONS and PRECAUTIONS , Drug Interactions , Amphotericin B injection and potassium-depleting agents ). Endocrine Hypothalamic-pituitary adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia. Monitor patients for these conditions with chronic use. Corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Drug induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Immunosuppression and Increased Risk of Infection Corticosteroids, including Methylprednisolone Sodium Succinate, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: Reduce resistance to new infection Exacerbate existing infections Increase the risk of disseminated infections Increase the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages. A study has failed to establish the efficacy of methylprednisolone sodium succinate in the treatment of sepsis syndrome and septic shock. The study also suggests that treatment of these conditions with methylprednisolone sodium succinate may increase the risk of mortality in certain patients (i.e., patients with elevated serum creatinine levels or patients who develop secondary infections after methylprednisolone sodium succinate). Monitor for the development of infection and consider methylprednisolone sodium succinate withdrawal or dosage reduction as needed. Tuberculosis If methylprednisolone sodium succinate is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of the disease may occur. Closely monitor such patients for reactivation. During prolonged methylprednisolone sodium succinate therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including methylprednisolone sodium succinate. In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles: If a methylprednisolone sodium succinate treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If varicella develops, treatment with antiviral agents may be considered. If a methylprednisolone sodium succinate treated patient is exposed to measles, prophylaxis with immunoglobulin (IG) may be indicated. Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including methylprednisolone sodium succinate. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with methylprednisolone sodium succinate. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy. Fungal Infections Corticosteroids, including methylprednisolone sodium succinate, may exacerbate systemic fungal infections; therefore, avoid methylprednisolone sodium succinate use in the presence of such infections unless methylprednisolone sodium succinate is needed to control drug reactions. For patients on chronic methylprednisolone sodium succinate therapy who develop systemic fungal infections, methylprednisolone sodium succinate withdrawal or dosage reduction is recommended. Amebiasis Corticosteroids, including methylprednisolone sodium succinate, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating methylprednisolone sodium succinate in patients who have spent time in the tropics or patients with unexplained diarrhea. Strongyloides Infestation Corticosteroids, including methylprednisolone sodium succinate, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Cerebral Malaria Avoid corticosteroids, including methylprednisolone sodium succinate, in patients with cerebral malaria. Drug-Induced Liver Injury Rarely, high doses of cyclically pulsed intravenous methylprednisolone (usually for the treatment of exacerbations of multiple sclerosis at doses of 1 gram/day) can induce a toxic form of acute hepatitis. The time to onset of this form of steroid-induced liver injury can be several weeks or longer. Resolution has been observed after discontinuation of treatment. However, serious liver injury can occur, sometimes resulting in acute liver failure and death. Discontinue intravenous methylprednisolone if toxic hepatitis occurs. Since recurrence has occurred after re-challenge, avoid use of high dose intravenous methylprednisolone in patients with a history of toxic hepatitis caused by methylprednisolone. Vaccination Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered. However, the response to such vaccines can not be predicted. Immunization procedures may be undertaken in patients receiving corticosteroids as replacement therapy, e.g., for Addison’s disease. Neurologic Reports of severe medical events have been associated with the intrathecal route of administration (see ADVERSE REACTIONS , Gastrointestinal and Neurologic/Psychiatric ). Ophthalmic Use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. The use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of corneal perforation. Corticosteroids should not be used in active ocular herpes simplex. Kaposi's Sarcoma Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma."],"pregnancy":["Pregnancy: Teratogenic effects: Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. This product when reconstituted with bacteriostatic water for injection contains benzyl alcohol as a preservative and the benzyl alcohol can cross the placenta. See PRECAUTIONS: Pediatric use ."],"overdosage":["OVERDOSAGE Treatment of acute overdosage is by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of the corticosteroid may be reduced only temporarily, or alternate day treatment may be introduced."],"description":["DESCRIPTION Methylprednisolone Sodium Succinate for Injection, USP, Sterile Powder is an anti-inflammatory glucocorticoid, which contains Methylprednisolone Sodium Succinate, USP as the active ingredient. Methylprednisolone Sodium Succinate, USP, is the sodium succinate ester of methylprednisolone, and it occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone. The chemical name for Methylprednisolone Sodium Succinate, USP, is pregna-1,4-diene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-6-methyl-monosodium salt, (6α, 11β), and the molecular weight is 496.53. The structural formula is represented below: Methylprednisolone Sodium Succinate, USP is soluble in water; it may be administered in a small volume of diluent and is well suited for intravenous use in situations where high blood levels of methylprednisolone are required rapidly. Methylprednisolone Sodium Succinate, USP, is available in two strengths and packages for intravenous or intramuscular administration: 40 mg (Single-Dose Vial) —Each mL (when mixed) contains Methylprednisolone Sodium Succinate, USP equivalent to 40 mg methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; 17.46 mg dibasic sodium phosphate dried; and 25 mg lactose hydrous. 125 mg (Single-Dose Vial) —Each 2 mL (when mixed) contains Methylprednisolone Sodium Succinate, USP equivalent to 125 mg methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried. IMPORTANT — Use only Water for Injection USP or Bacteriostatic Water for Injection USP with Benzyl Alcohol when reconstituting Methylprednisolone Sodium Succinate for Injection, USP. Use within 48 hours after mixing. When necessary, the pH of each formula was adjusted with sodium hydroxide so that the pH of the reconstituted solution is within the USP specified range of 7 to 8. chemical structure"],"precautions":["PRECAUTIONS General This product, like many other steroid formulations, is sensitive to heat. Therefore, it should not be autoclaved when it is desirable to sterilize the exterior of the vial. The lowest possible dose of corticosteroid should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual. Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used. Cardio-renal Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone. As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Endocrine Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage. Gastrointestinal Steroids should be used with caution in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of a perforation. Signs of peritoneal irritation following gastrointestinal perforation in patients receiving corticosteroids may be minimal or absent. There is an enhanced effect due to decreased metabolism of corticosteroids in patients with cirrhosis. Musculoskeletal Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Special consideration should be given to patients at increased risk of osteoporosis (i.e., postmenopausal women) before initiating corticosteroid therapy. Local injection of a steroid into a previously infected site is not usually recommended. Neurologic-psychiatric Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See DOSAGE AND ADMINISTRATION ) An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevations of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years. Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Ophthalmic Intraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored. Tumor Lysis Syndrome In post marketing experience, tumor lysis syndrome (TLS) has been reported in patients with malignancies, including hematological malignancies and solid tumors, following the use of systemic corticosteroids alone or in combination with other chemotherapeutic agents. Patients at high risk of TLS, such as patients with tumors that have a high proliferative rate, high tumor burden and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precautions should be taken. Information for Patients Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision, to advise any medical attendants that they are taking corticosteroids, and to seek medical advice at once should they develop fever or other signs of infection. Persons who are on corticosteroids should be warned to avoid exposure to chicken pox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay. Drug Interactions Aminoglutethimide Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. Amphotericin B injection and potassium-depleting agents When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions, Hepatic Enzyme Inhibitors ). Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs Serum concentrations of isoniazid may be decreased. Cholestyramine Cholestyramine may increase the clearance of corticosteroids. Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Digitalis glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Estrogens, including oral contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin) Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids. Ketoconazole Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Nonsteroidal anti-inflammatory agents (NSAIDs) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Skin tests Corticosteroids may suppress reactions to skin tests. Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Immunosuppression and Increased Risk of Infection , Vaccination ). Carcinogenesis, Mutagenesis, Impairment of Fertility No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis. Steroids may increase or decrease motility and number of spermatozoa in some patients. Corticosteroids have been shown to impair fertility in male rats. Pregnancy: Teratogenic effects: Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. This product when reconstituted with bacteriostatic water for injection contains benzyl alcohol as a preservative and the benzyl alcohol can cross the placenta. See PRECAUTIONS: Pediatric use . Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a decision should be made whether to continue nursing, or discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use This product when reconstituted with bacteriostatic water for injection contains benzyl alcohol as a preservative (see DESCRIPTION ). Benzyl alcohol, a component of this product, has been associated with serious adverse events and death, particularly in pediatric patients. The \"gasping syndrome\" (characterized by central nervous system depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages >99 mg/kg/day in neonates and low-birth-weight neonates. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Although normal therapeutic doses of this product ordinarily delivers amounts of benzyl alcohol that are substantially lower than those reported in association with the \"gasping syndrome\", the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the hepatic capacity to detoxify the chemical. Premature and low-birth-weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources. The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephrotic syndrome (>2 years of age), and aggressive lymphomas and leukemias (>1 month of age). Other indications for pediatric use of corticosteroids, e.g., severe asthma and wheezing, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations. The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see ADVERSE REACTIONS ). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose. Hypertrophic cardiomyopathy may develop after administration of methylprednisolone to prematurely born infants, therefore appropriate diagnostic evaluation and monitoring of cardiac function and structure should be performed. Geriatric Use Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED Methylprednisolone Sodium Succinate for Injection, USP is available in the following packages: NDC Strength Unit of Sale 0143-9753-25 40 mg (Single-Dose Vial) Carton of 25 vials 0143-9754-25 125 mg (Single-Dose Vial) Carton of 25 vials Manufactured by: HIKMA FARMACÊUTICA (PORTUGAL), S.A. Estrada do Rio da Mó, nº 8, 8A e 8B – Fervença, 2705 – 906 Terrugem SNT PORTUGAL Distributed by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 PIN520-WES/8 Revised: January 2025"],"geriatric_use":["Geriatric Use Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["Pediatric Use This product when reconstituted with bacteriostatic water for injection contains benzyl alcohol as a preservative (see DESCRIPTION ). Benzyl alcohol, a component of this product, has been associated with serious adverse events and death, particularly in pediatric patients. The \"gasping syndrome\" (characterized by central nervous system depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages >99 mg/kg/day in neonates and low-birth-weight neonates. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Although normal therapeutic doses of this product ordinarily delivers amounts of benzyl alcohol that are substantially lower than those reported in association with the \"gasping syndrome\", the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the hepatic capacity to detoxify the chemical. Premature and low-birth-weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources. The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephrotic syndrome (>2 years of age), and aggressive lymphomas and leukemias (>1 month of age). Other indications for pediatric use of corticosteroids, e.g., severe asthma and wheezing, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations. The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see ADVERSE REACTIONS ). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose. Hypertrophic cardiomyopathy may develop after administration of methylprednisolone to prematurely born infants, therefore appropriate diagnostic evaluation and monitoring of cardiac function and structure should be performed."],"effective_time":"20250102","nursing_mothers":["Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a decision should be made whether to continue nursing, or discontinue the drug, taking into account the importance of the drug to the mother."],"adverse_reactions":["ADVERSE REACTIONS The following adverse reactions have been reported with methylprednisolone sodium succinate or other corticosteroids: Allergic reactions: Allergic or hypersensitivity reactions, anaphylactoid reaction, anaphylaxis, angioedema. Blood and lymphatic system disorders: Leukocytosis. Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see WARNINGS ), pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis. Dermatologic: Acne, allergic dermatitis, burning or tingling (especially in the perineal area after intravenous injection), cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients. Fluid and electrolyte disturbances: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention. Gastrointestinal: Abdominal distention, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis. Hepatobiliary: Hepatitis (see WARNINGS , Drug-Induced Liver Injury ). Metabolic: Negative nitrogen balance due to protein catabolism. Musculoskeletal: Aseptic necrosis of femoral and humeral heads, Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, postinjection flare (following intra-articular use), steroid myopathy, tendon rupture, vertebral compression fractures. Neurologic/Psychiatric: Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo. Arachnoiditis, meningitis, paraparesis/paraplegia, and sensory disturbances have occurred after intrathecal administration (see WARNINGS, Neurologic ). Ophthalmic: Exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts, rare instances of blindness associated with periocular injections. Other: Abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, injection site infections following non-sterile administration (see WARNINGS ), malaise, moon face, weight gain. To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Methylprednisolone Sodium Succinate Sterile Powder is contraindicated: in systemic fungal infections and patients with known hypersensitivity to the product and its constituents; The methylprednisolone sodium succinate for injection 40 mg presentation includes lactose monohydrate produced from cow’s milk. This presentation is therefore contraindicated in patients with a known or suspected hypersensitivity to cow’s milk or its components or other dairy products because it may contain trace amounts of milk ingredients. for intrathecal administration. Reports of severe medical events have been associated with this route of administration. Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. Additional contraindication for the use of Methylprednisolone Sodium Succinate Sterile Powder preserved with benzyl alcohol: Formulations preserved with benzyl alcohol are contraindicated for use in premature infants (see WARNINGS and PRECAUTIONS, Pediatric Use )."],"drug_interactions":["Drug Interactions Aminoglutethimide Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. Amphotericin B injection and potassium-depleting agents When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions, Hepatic Enzyme Inhibitors ). Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs Serum concentrations of isoniazid may be decreased. Cholestyramine Cholestyramine may increase the clearance of corticosteroids. Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Digitalis glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Estrogens, including oral contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin) Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids. Ketoconazole Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Nonsteroidal anti-inflammatory agents (NSAIDs) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Skin tests Corticosteroids may suppress reactions to skin tests. Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Immunosuppression and Increased Risk of Infection , Vaccination )."],"how_supplied_table":["<table width=\"413.05pt\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"1pt\"/><col width=\"154.25pt\"/><col width=\"104.55pt\"/><tbody><tr><td><paragraph><content styleCode=\"bold\">NDC</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Strength</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Unit of Sale</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0143-9753-25</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>40 mg (Single-Dose Vial)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Carton of 25 vials</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0143-9754-25</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>125 mg (Single-Dose Vial)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Carton of 25 vials</paragraph></td></tr></tbody></table>"],"general_precautions":["General This product, like many other steroid formulations, is sensitive to heat. Therefore, it should not be autoclaved when it is desirable to sterilize the exterior of the vial. The lowest possible dose of corticosteroid should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual. Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used."],"storage_and_handling":["STORAGE CONDITIONS Protect from light. Store unreconstituted product at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]. Store reconstituted solution (not further diluted) at controlled room temperature 20° to 25°C (68° to 77°F) [see USP], and use it within 48 hours. See section DOSAGE AND ADMINISTRATION , for storage of further diluted solution."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Methylprednisolone is a potent anti-inflammatory steroid with greater anti-inflammatory potency than prednisolone and even less tendency than prednisolone to induce sodium and water retention. Methylprednisolone sodium succinate has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. Following the intravenous injection of methylprednisolone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection."],"indications_and_usage":["INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of Methylprednisolone Sodium Succinate for Injection is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Note: Methylprednisolone sodium succinate injection when reconstituted with bacteriostatic water for injection contains benzyl alcohol (see DESCRIPTION , WARNINGS and PRECAUTIONS , Pediatric Use) Because of possible physical incompatibilities, methylprednisolone sodium succinate should not be diluted or mixed with other solutions. Use only Water for Injection or Bacteriostatic Water For Injection with Benzyl Alcohol when reconstituting methylprednisolone sodium succinate (see DESCRIPTION ). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. This preparation may be administered by intravenous injection, by intravenous infusion, or by intramuscular injection, the preferred method for initial emergency use being intravenous injection. Following the initial emergency period, consideration should be given to employing a longer acting injectable preparation or an oral preparation. There are reports of cardiac arrhythmias and/or cardiac arrest following the rapid administration of large intravenous doses of methylprednisolone sodium succinate ( greater than 0.5 gram administered over a period of less than 10 minutes ). Bradycardia has been reported during or after the administration of large doses of methylprednisolone sodium succinate and may be unrelated to the speed or duration of infusion. When high dose therapy is desired, the recommended dose of methylprednisolone sodium succinate sterile powder is 30 mg/kg administered intravenously over at least 30 minutes . This dose may be repeated every 4 to 6 hours for 48 hours. In general, high dose corticosteroid therapy should be continued only until the patient's condition has stabilized; usually not beyond 48 to 72 hours. In other indications, initial dosage will vary from 10 to 40 mg of methylprednisolone depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administrations in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. It Should Be Emphasized that Dosage Requirements are Variable and Must Be Individualized on the Basis of the Disease Under Treatment and the Response of the Patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation, it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. Methylprednisolone sodium succinate for injection may be administered by intravenous or intramuscular injection or by intravenous infusion, the preferred method for initial emergency use being intravenous injection. To administer by intravenous (or intramuscular) injection, prepare solution as directed. The desired dose may be administered intravenously over a period of several minutes. If desired, the medication may be administered in diluted solutions by adding Water for Injection or other suitable diluent, withdrawing the indicated dose. To prepare solutions for intravenous infusion, first prepare the solution for injection as directed. This solution may then be added to indicated amounts of 5% dextrose in water, isotonic saline solution, or 5% dextrose in isotonic saline solution. From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. Chemical and physical stability of the further diluted product has been demonstrated within 4 hours of preparation if stored below 25°C or within 24 hours of preparation if stored at 2°C to 8°C. In pediatric patients, the initial dose of methylprednisolone may vary depending on the specific disease entity being treated. The range of initial doses is 0.11 to 1.6 mg/kg/day in three or four divided doses (3.2 to 48 mg/m 2 bsa/day). The National Heart, Lung, and Blood Institute (NHLBI) recommended dosing for systemic prednisone, prednisolone, or methylprednisolone in pediatric patients whose asthma is uncontrolled by inhaled corticosteroids and long-acting bronchodilators is 1–2 mg/kg/day in single or divided doses. It is further recommended that short course, or \"burst\" therapy, be continued until the patient achieves a peak expiratory flow rate of 80% of his or her personal best or until symptoms resolve. This usually requires 3 to 10 days of treatment, although it can take longer. There is no evidence that tapering the dose after improvement will prevent a relapse. Dosage may be reduced for infants and children but should be governed more by the severity of the condition and response of the patient than by age or size. It should not be less than 0.5 mg per kg every 24 hours. Dosage must be decreased or discontinued gradually when the drug has been administered for more than a few days. If a period of spontaneous remission occurs in a chronic condition, treatment should be discontinued. Routine laboratory studies, such as urinalysis, two-hour postprandial blood sugar, determination of blood pressure and body weight, and a chest X-ray should be made at regular intervals during prolonged therapy. Upper GI X-rays are desirable in patients with an ulcer history or significant dyspepsia. In treatment of acute exacerbations of multiple sclerosis, daily doses of 160 mg of methylprednisolone for a week followed by 64 mg every other day for 1 month have been shown to be effective (see PRECAUTIONS, Neurologic-psychiatric ). For the purpose of comparison, the following is the equivalent milligram dosage of the various glucocorticoids: Cortisone, 25 Triamcinolone, 4 Hydrocortisone, 20 Paramethasone, 2 Prednisolone, 5 Betamethasone, 0.75 Prednisone, 5 Dexamethasone, 0.75 Methylprednisolone, 4 These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered."],"spl_product_data_elements":["Methylprednisolone Sodium Succinate Methylprednisolone Sodium Succinate METHYLPREDNISOLONE SODIUM SUCCINATE METHYLPREDNISOLONE SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS SODIUM PHOSPHATE, DIBASIC SODIUM HYDROXIDE Methylprednisolone Sodium Succinate Methylprednisolone Sodium Succinate METHYLPREDNISOLONE SODIUM SUCCINATE METHYLPREDNISOLONE SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS SODIUM PHOSPHATE, DIBASIC LACTOSE MONOHYDRATE SODIUM HYDROXIDE"],"dosage_and_administration_table":["<table><col/><col/><tbody><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Cortisone, 25</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Triamcinolone, 4</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Hydrocortisone, 20</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Paramethasone, 2</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Prednisolone, 5</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Betamethasone, 0.75 </paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Prednisone, 5</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Dexamethasone, 0.75</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Methylprednisolone, 4</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"/></tr></tbody></table>"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 0143- 9753 -01 Rx only methylPREDNISolone Sodium Succinate for Injection, USP 40 mg per vial For Intramuscular or Intravenous Use ONLY Single-Dose Vial methylPREDNISolone Sodium Succinate for Injection USP 40 mg vial NDC 0143- 9753 -25 Rx only methylPREDNISolone Sodium Succinate for Injection, USP 40 mg per vial For Intramuscular or Intravenous Use ONLY This Package Does Not Contain Diluent. The Recommended Diluents are Water for Injection USP or Bacteriostatic Water for Injection USP. Bacteriostatic Water for Injection USP Contains Benzyl Alcohol as a Preservative. 25 Single-Dose Vials methylPREDNISolone Sodium Succinate for Injection USP 40 mg carton methylPREDNISolone Sodium Succinate for Injection USP 40 mg vial methylPREDNISolone Sodium Succinate for Injection USP 40 mg carton","PRINCIPAL DISPLAY PANEL NDC 0143- 9754 -01 methylPREDNISolone Sodium Succinate for Injection, USP 125 mg per vial For Intramuscular or Intravenous Use ONLY Single-Dose Vial methylPREDNISolone Sodium Succinate for Injection USP 125 mg vial NDC 0143- 9754 -25 methylPREDNISolone Sodium Succinate for Injection, USP 125 mg per vial For Intramuscular or Intravenous Use ONLY This Package Does Not Contain Diluent. The Recommended Diluents are Water for Injection USP or Bacteriostatic Water for Injection USP. Bacteriostatic Water for Injection USP Contains Benzyl Alcohol as a Preservative. 25 Single-Dose Vials methylPREDNISolone Sodium Succinate for Injection USP 125 mg carton methylPREDNISolone Sodium Succinate for Injection USP 125 mg vial methylPREDNISolone Sodium Succinate for Injection USP 125 mg carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis. Steroids may increase or decrease motility and number of spermatozoa in some patients. Corticosteroids have been shown to impair fertility in male rats."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Approved 1970s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Aminoglutethimide","severity":"moderate","mechanism":"May lead to a loss of corticosteroid-induced adrenal suppression","management":"Monitor adrenal function","clinicalEffect":"Potential loss of adrenal suppression"},{"drug":"Amphotericin B injection and potassium-depleting agents","severity":"major","mechanism":"Corticosteroids may exacerbate potassium depletion","management":"Monitor potassium levels and cardiac function; consider alternative therapies","clinicalEffect":"Development of hypokalemia; cardiac enlargement and congestive heart failure"},{"drug":"Macrolide antibiotics","severity":"moderate","mechanism":"Decrease in corticosteroid clearance","management":"Monitor corticosteroid levels and adjust dose if necessary","clinicalEffect":"Increased corticosteroid levels"},{"drug":"Anticholinesterases","severity":"major","mechanism":"Severe weakness in patients with myasthenia gravis","management":"Withdraw anticholinesterase agents at least 24 hours before starting corticosteroids","clinicalEffect":"Severe muscle weakness"},{"drug":"Oral anticoagulants (e.g., warfarin)","severity":"moderate","mechanism":"Inhibition of response to warfarin","management":"Monitor coagulation indices and adjust anticoagulant dose as needed","clinicalEffect":"Altered anticoagulant effect"},{"drug":"Antidiabetics","severity":"moderate","mechanism":"Corticosteroids may increase blood glucose concentrations","management":"Adjust antidiabetic agent dosage as needed","clinicalEffect":"Increased blood glucose"},{"drug":"Antitubercular drugs (e.g., isoniazid)","severity":"moderate","mechanism":"Decreased serum concentrations of isoniazid","management":"Monitor isoniazid levels and adjust dose if necessary","clinicalEffect":"Reduced efficacy of isoniazid"},{"drug":"Cholestyramine","severity":"moderate","mechanism":"Increased clearance of corticosteroids","management":"Monitor corticosteroid levels and adjust dose if necessary","clinicalEffect":"Decreased corticosteroid levels"},{"drug":"Cyclosporine","severity":"major","mechanism":"Increased activity of both drugs","management":"Monitor for side effects and consider dose adjustment","clinicalEffect":"Increased risk of side effects; convulsions"},{"drug":"Digitalis glycosides","severity":"major","mechanism":"Increased risk of arrhythmias due to hypokalemia","management":"Monitor potassium levels and ECG; consider alternative therapies","clinicalEffect":"Arrhythmias"},{"drug":"Estrogens, including oral contraceptives","severity":"moderate","mechanism":"Decreased hepatic metabolism of corticosteroids","management":"Monitor corticosteroid levels and adjust dose if necessary","clinicalEffect":"Increased corticosteroid effect"},{"drug":"Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin)","severity":"moderate","mechanism":"Enhanced metabolism of corticosteroids","management":"Increase corticosteroid dose if necessary","clinicalEffect":"Decreased corticosteroid levels"},{"drug":"Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin)","severity":"major","mechanism":"Decreased metabolism of corticosteroids","management":"Monitor corticosteroid levels and reduce dose if necessary","clinicalEffect":"Increased corticosteroid levels and side effects"},{"drug":"Ketoconazole","severity":"major","mechanism":"Significantly decreases metabolism of corticosteroids","management":"Monitor corticosteroid levels and reduce dose if necessary","clinicalEffect":"Increased corticosteroid levels and side effects"},{"drug":"Nonsteroidal anti-inflammatory agents (NSAIDs)","severity":"moderate","mechanism":"Increased risk of gastrointestinal side effects","management":"Use caution; monitor for gastrointestinal symptoms","clinicalEffect":"Gastrointestinal adverse events"}],"commonSideEffects":[{"effect":"Fluid retention","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased appetite","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Weight gain","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"","severity":"common","organSystem":""},{"effect":"Acne","drugRate":"","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"","severity":"common","organSystem":""},{"effect":"Mood swings","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased sweating","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"","severity":"common","organSystem":""},{"effect":"Potassium loss","drugRate":"","severity":"common","organSystem":""},{"effect":"Muscle weakness","drugRate":"","severity":"common","organSystem":""},{"effect":"Osteoporosis","drugRate":"","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"","severity":"common","organSystem":""},{"effect":"Emotional instability","drugRate":"","severity":"common","organSystem":""},{"effect":"Decreased resistance to infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Moon face","drugRate":"","severity":"common","organSystem":""}],"contraindications":["in systemic fungal infections and patients with known hypersensitivity to the product and its constituents","in patients with a known or suspected hypersensitivity to cow’s milk or its components or other dairy products due to potential trace amounts of milk ingredients in the 40 mg presentation","for intrathecal administration due to reports of severe medical events","for idiopathic thrombocytopenic purpura when administered intramuscularly","formulations preserved with benzyl alcohol are contraindicated for use in premature infants"],"seriousAdverseEvents":[{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Cardiac arrest","drugRate":"","severity":"serious"},{"effect":"Circulatory collapse","drugRate":"","severity":"serious"},{"effect":"Myocardial rupture","drugRate":"","severity":"serious"},{"effect":"Pulmonary edema","drugRate":"","severity":"serious"},{"effect":"Peptic ulcer with perforation and hemorrhage","drugRate":"","severity":"serious"},{"effect":"Aseptic necrosis of femoral and humeral heads","drugRate":"","severity":"serious"},{"effect":"Convulsions","drugRate":"","severity":"serious"},{"effect":"Increased intracranial pressure with papilledema","drugRate":"","severity":"serious"},{"effect":"Blindness associated with periocular injections","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SODIUM SUCCINATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:07:29.332277+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:10:12.814260+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:07:35.983468+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SODIUM SUCCINATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:07:36.358136+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:07:28.222210+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:10:02.076357+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:07:28.222243+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:08:58.109262+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200345/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:07:37.692205+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS The following adverse reactions have been reported with methylprednisolone sodium succinate or other corticosteroids: Allergic reactions: Allergic or hypersensitivity reactions, anaphylactoid reaction, anaphylaxis, angioedema. Blood and lymphatic system disorders: Leukocytosis. Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:07:41.790740+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:07:48.604841+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA203125","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:07:28.222248+00:00"}},"allNames":["sodium succinate"],"offLabel":[],"synonyms":["sodium succinate"],"timeline":[{"date":"1971-11-16","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Sodium succinate is a marketed drug primarily indicated for allergic states, with a key composition patent expiring in 2028. Its mechanism of providing succinate ions to regulate cellular processes offers a unique therapeutic approach in managing allergic conditions. The primary risk is the potential increase in competition following the patent expiry in 2028.","approvals":[{"date":"1971-11-16","orphan":false,"company":"","regulator":"FDA"}],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Sodium succinate is a small molecule that acts as a source of succinate ions, which can be used by cells to produce ATP through the citric acid cycle and oxidative phosphorylation."},"commercial":{"launchDate":"1971","_launchSource":"DrugCentral (FDA 1971-11-16, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5200","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SODIUM%20SUCCINATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SODIUM SUCCINATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:41:12.530846","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T03:10:12.814370+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"sodium succinate","indications":{"approved":[{"id":"sodium-succinate-allergic-states","name":"Allergic States","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with severe or incapacitating allergic conditions","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with severe or incapacitating allergic conditions","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-dermatologic-diseases","name":"Dermatologic Diseases","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with specified dermatologic diseases","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with specified dermatologic diseases","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-endocrine-disorders","name":"Endocrine Disorders","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with endocrine disorders","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with endocrine disorders","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-gastrointestinal-diseases","name":"Gastrointestinal Diseases","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with gastrointestinal diseases during critical periods","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with gastrointestinal diseases during critical periods","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-hematologic-disorders","name":"Hematologic Disorders","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with hematologic disorders","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with hematologic disorders","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-miscellaneous","name":"Miscellaneous","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with trichinosis or tuberculous meningitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with trichinosis or tuberculous meningitis","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-neoplastic-diseases","name":"Neoplastic Diseases","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with leukemias and lymphomas","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with leukemias and lymphomas","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-nervous-system","name":"Nervous System","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with nervous system conditions","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with nervous system conditions","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-ophthalmic-diseases","name":"Ophthalmic Diseases","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with ophthalmic diseases","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with ophthalmic diseases","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-renal-diseases","name":"Renal Diseases","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with renal diseases","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with renal diseases","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-respiratory-diseases","name":"Respiratory Diseases","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with respiratory diseases","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with respiratory diseases","diagnosticRequired":null,"brandNameForIndication":""},{"id":"sodium-succinate-rheumatic-disorders","name":"Rheumatic Disorders","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with rheumatic disorders","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with rheumatic disorders","diagnosticRequired":null,"brandNameForIndication":""}],"offLabel":[],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT02068586","phase":"PHASE2","title":"Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2014-11-19","conditions":["Ciliary Body and Choroid Melanoma, Medium/Large Size","Ciliary Body and Choroid Melanoma, Small Size","Iris Melanoma","Stage I Intraocular Melanoma","Stage IIA Intraocular Melanoma","Stage IIB Intraocular Melanoma","Stage IIIA Intraocular Melanoma","Stage IIIB Intraocular Melanoma","Stage IIIC Intraocular Melanoma","Stage I Uveal Melanoma AJCC V7","Stage II Uveal Melanoma AJCC V7","Stage III Uveal Melanoma AJCC V7"],"enrollment":210,"completionDate":"2026-12-31"},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":["Myelodysplastic Syndromes, de Novo","Myelodysplastic Syndromes, Secondary","Myelodysplastic Syndromes, Previously Treated","Treatment-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Lymphoblastic Lymphoma, in Relapse","Lymphoblastic Lymphoma, Refractory","Acute Leukemia of Ambiguous Lineage in Relapse","Acute Leukemia of Ambiguous Lineage"],"enrollment":30,"completionDate":"2030-07-02"},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":["Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","Steroid-Refractory Pneumonitis"],"enrollment":1,"completionDate":"2023-12-21"},{"nctId":"NCT06247787","phase":"PHASE1","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-04","conditions":["Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Myelodysplastic Syndrome","Recurrent Juvenile Myelomonocytic Leukemia","Refractory Childhood Acute Myeloid Leukemia","Refractory Childhood Myelodysplastic Syndrome","Refractory Juvenile Myelomonocytic Leukemia"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT07268248","phase":"NA","title":"1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study","status":"NOT_YET_RECRUITING","sponsor":"Paul Peng, MD PhD MSCR","startDate":"2026-06","conditions":["Allergic Reaction to Contrast Media","Hypersensitivity Reaction","Computed Tomography","Premedication"],"enrollment":540,"completionDate":"2028-06"},{"nctId":"NCT07208799","phase":"PHASE2","title":"Comparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures","status":"RECRUITING","sponsor":"Nishtar Medical University","startDate":"2026-01-03","conditions":["Mandible Fracture","Edema Face","Pain Management","Corticosteroid Injection"],"enrollment":72,"completionDate":"2026-12-01"},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":["Pneumococcal Infections"],"enrollment":310,"completionDate":"2024-05-28"},{"nctId":"NCT07054801","phase":"PHASE2","title":"IA Lidocaine and Methylprednisolone for Headache Associated With Subarachnoid Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Daniel Raper, MBBS","startDate":"2026-03-01","conditions":["Headaches Associated With Subarachnoid Hemorrhage (SAH)"],"enrollment":25,"completionDate":"2027-12-01"},{"nctId":"NCT07353749","phase":"PHASE4","title":"Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms","status":"NOT_YET_RECRUITING","sponsor":"Duan Chuanzhi","startDate":"2026-01-30","conditions":["Unruptured Intracranial Aneurysms","Cerebrovascular Event","Hemorrhagic Stroke","Methylprednisolone","Flow Diverter"],"enrollment":864,"completionDate":"2027-09-01"},{"nctId":"NCT07317596","phase":"PHASE3","title":"Comparing Methylprednisolone And Hyaluronic Acid To Reduce Wisdom Tooth Surgery Complications","status":"ENROLLING_BY_INVITATION","sponsor":"Sana'a University","startDate":"2024-06-27","conditions":["Wisdom Tooth Removal","Post Operative Complications","Hyaluronic Acid","Methylprednisolone"],"enrollment":40,"completionDate":"2026-01-08"},{"nctId":"NCT07328880","phase":"NA","title":"4-L Split-dose Polyethylene Glycol and Bisacodyl and Docusate Sodium Regimen Versus 2-L Split-dose Polyethylene Glycol Plus Oral Simethicone Regimen for Bowel Preparation Before Colonoscopy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-04-01","conditions":["Colonoscopy Preparation"],"enrollment":450,"completionDate":"2026-04-26"},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":["Recurrent Acute Leukemia of Ambiguous Lineage","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Refractory Acute Leukemia of Ambiguous Lineage","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged","Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia","Refractory Mixed Phenotype Acute Leukemia"],"enrollment":78,"completionDate":"2027-12-31"},{"nctId":"NCT07262957","phase":"PHASE4","title":"Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-09-01","conditions":["Pancreas Head Cancer","Pancreas Adenocarcinoma","IPMN, Pancreatic","Cholangio Carcinoma","Ampulla of Vater Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Duodenal Carcinoma","Mucinous Cystic Neoplasm","Neuro Endocrine Tumours","Pancreatitis"],"enrollment":400,"completionDate":"2027-12-01"},{"nctId":"NCT07271394","phase":"","title":"The Impact of Methylprednisolone Sodium Succinate on Postoperative Delirium in Elderly Patients Undergoing Abdominal Surgery: A Target Trial Emulation Study","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2018-10-01","conditions":["Postoperative Delirium (POD)"],"enrollment":25800,"completionDate":"2021-10-01"},{"nctId":"NCT06360458","phase":"PHASE3","title":"Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wan-Jin Chen","startDate":"2024-08-01","conditions":["Acute Ischemic Stroke","Large Infarct Core"],"enrollment":928,"completionDate":"2030-06-30"},{"nctId":"NCT07257588","phase":"NA","title":"The Efficacy of Hyperbaric Oxygen-assisted Treatment for ASUC and Refractory IBD","status":"ENROLLING_BY_INVITATION","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-09-30","conditions":["Ulcerative Colitis"],"enrollment":44,"completionDate":"2025-12-31"},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":["Adult T Acute Lymphoblastic Leukemia","Ann Arbor Stage II Adult Lymphoblastic Lymphoma","Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","Ann Arbor Stage III Adult Lymphoblastic Lymphoma","Ann Arbor Stage III Childhood Lymphoblastic Lymphoma","Ann Arbor Stage IV Adult Lymphoblastic Lymphoma","Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma","Childhood T Acute Lymphoblastic Leukemia"],"enrollment":847,"completionDate":"2026-09-16"},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","Central Nervous System Leukemia","Testicular Leukemia"],"enrollment":5949,"completionDate":"2026-10-03"},{"nctId":"NCT06462781","phase":"PHASE1","title":"Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1","status":"COMPLETED","sponsor":"The Cooper Health System","startDate":"2024-03-15","conditions":["Refractory Migraine"],"enrollment":10,"completionDate":"2025-06-01"},{"nctId":"NCT03401398","phase":"PHASE3","title":"Stress Hydrocortisone In Pediatric Septic Shock","status":"RECRUITING","sponsor":"Jerry Zimmerman","startDate":"2019-03-11","conditions":["Septic Shock"],"enrollment":500,"completionDate":"2026-12-31"},{"nctId":"NCT07202143","phase":"PHASE3","title":"Methylprednisolone for Stroke With Large Infarct Core and Post-stroke Lymphocytopenia","status":"RECRUITING","sponsor":"YiLin","startDate":"2025-09-01","conditions":["Large Infarct Core","Post-stroke Lymphocytopenia"],"enrollment":200,"completionDate":"2027-09-30"},{"nctId":"NCT07185633","phase":"PHASE2","title":"Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease","status":"NOT_YET_RECRUITING","sponsor":"Bin Gu","startDate":"2025-10-01","conditions":["aGVHD"],"enrollment":25,"completionDate":"2027-10-01"},{"nctId":"NCT07141303","phase":"PHASE3","title":"Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-08-08","conditions":["Acute Ischemic Stroke"],"enrollment":1060,"completionDate":"2028-06-30"},{"nctId":"NCT07180277","phase":"PHASE4","title":"Methylprednisolone for Moderate to Severe Traumatic Brain Injury","status":"NOT_YET_RECRUITING","sponsor":"Zhangjiagang First People's Hospital","startDate":"2025-10-01","conditions":["Traumatic Brain Injury"],"enrollment":520,"completionDate":"2028-03-01"},{"nctId":"NCT07175649","phase":"NA","title":"Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-10","conditions":["Ischemic Stroke, Acute"],"enrollment":912,"completionDate":"2029-12"},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":["Down Syndrome","Recurrent B Acute Lymphoblastic Leukemia"],"enrollment":461,"completionDate":"2028-06-30"},{"nctId":"NCT05935787","phase":"PHASE3","title":"Cytoflavin in the Complex Rehabilitation of Stroke Patients","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2023-06-09","conditions":["Stroke"],"enrollment":240,"completionDate":"2024-12-07"},{"nctId":"NCT07116811","phase":"PHASE3","title":"Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-09-01","conditions":["Vestibular Schwannoma","Facial Nerve Paralysis"],"enrollment":364,"completionDate":"2027-09-30"},{"nctId":"NCT05682261","phase":"NA","title":"The Effect of Multiple Micronutrient Supplements in Reducing Anemia in Women of Reproductive Age","status":"COMPLETED","sponsor":"Ethiopian Public Health Institute","startDate":"2023-03-23","conditions":["Anemia"],"enrollment":265,"completionDate":"2023-10-17"},{"nctId":"NCT00001337","phase":"PHASE2","title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1993-05-08","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)","Primary Mediastinal Large B-cell Lymphoma","Burkitt Lymphoma","Anaplastic Large-Cell Lymphoma","Gray Zone Lymphoma"],"enrollment":348,"completionDate":"2024-05-24"},{"nctId":"NCT07025876","phase":"EARLY_PHASE1","title":"PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2023-11-18","conditions":["Streptococcus Pneumoniae Pneumonia"],"enrollment":240,"completionDate":"2024-07-30"},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":112,"completionDate":"2020-03"},{"nctId":"NCT06984432","phase":"NA","title":"Evaluation of a Non-cross-linked Hyaluronic Acid Medical Device (\"Electri\" and \"XELA REDERM\") for Improving Facial Skin Appearance","status":"COMPLETED","sponsor":"Institute Hyalual GmbH","startDate":"2021-03-30","conditions":["Appearance of Facial Wrinkles","Aesthetic","Hydration","Facial Skin Wrinkles"],"enrollment":77,"completionDate":"2021-10-29"},{"nctId":"NCT06374641","phase":"NA","title":"The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive Function","status":"RECRUITING","sponsor":"University of Exeter","startDate":"2024-03-26","conditions":["Exercise Performance","Cognitive Function"],"enrollment":40,"completionDate":"2025-10"},{"nctId":"NCT04631484","phase":"PHASE3","title":"International Trial of Efficacy of Cytoflavin in Head Trauma","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2020-11-22","conditions":["Head Trauma,Closed"],"enrollment":166,"completionDate":"2024-09-24"},{"nctId":"NCT06924983","phase":"PHASE4","title":"Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Basal Ganglia Intracerebral Hemorrhage at the Early Stage","status":"NOT_YET_RECRUITING","sponsor":"Yong Jiang","startDate":"2025-05-01","conditions":["Stroke","Intracerebral Hemorrhage Basal Ganglia","Methylprednisolone","Surgery"],"enrollment":100,"completionDate":"2027-01-31"},{"nctId":"NCT06921616","phase":"PHASE4","title":"Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.","status":"NOT_YET_RECRUITING","sponsor":"Yong Jiang","startDate":"2025-05-01","conditions":["Stroke","Intracerebral Hemorrhage Lobar","Methylprednisolone","Surgery"],"enrollment":396,"completionDate":"2027-01-31"},{"nctId":"NCT04662723","phase":"PHASE4","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","status":"RECRUITING","sponsor":"Fondazione Schena","startDate":"2023-05-01","conditions":["Glomerulonephritis","Immunoglobulin A Nephropathy"],"enrollment":878,"completionDate":"2028-12-31"},{"nctId":"NCT06870448","phase":"PHASE3","title":"Methylprednisolone With Endovascular Thrombectomy for Large Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-04","conditions":["Acute Ischemic Stroke"],"enrollment":1614,"completionDate":"2029-04"},{"nctId":"NCT06635720","phase":"PHASE3","title":"REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)","status":"RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2024-11-01","conditions":["Nephrotic Syndrome in Children","Nephrotic Syndrome, Minimal Change","Nephrotic Syndrome","Nephrotic Syndrome，Idiopathic"],"enrollment":50,"completionDate":"2026-11-30"},{"nctId":"NCT02828358","phase":"PHASE2","title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-01","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia"],"enrollment":78,"completionDate":"2024-12-31"},{"nctId":"NCT01353313","phase":"PHASE3","title":"Hydrocortisone for BPD","status":"COMPLETED","sponsor":"NICHD Neonatal Research Network","startDate":"2011-08-11","conditions":["Infant, Newborn","Infant, Small for Gestational Age","Infant, Very Low Birth Weight","Infant, Premature","Bronchopulmonary Dysplasia"],"enrollment":800,"completionDate":"2024-09-12"},{"nctId":"NCT04826588","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)","status":"COMPLETED","sponsor":"University Children's Hospital Basel","startDate":"2021-05-23","conditions":["Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)"],"enrollment":76,"completionDate":"2022-11-20"},{"nctId":"NCT05172180","phase":"","title":"Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2020-12-01","conditions":["COVID-19"],"enrollment":105,"completionDate":"2021-04-01"},{"nctId":"NCT05423249","phase":"NA","title":"Treatment of Non-Anemic Iron Deficiency in Pregnancy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2022-08-12","conditions":["Non-anemic Iron Deficiency"],"enrollment":150,"completionDate":"2024-11-15"},{"nctId":"NCT06678607","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older","status":"COMPLETED","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2023-11-19","conditions":["Pneumococcal Infectious Disease"],"enrollment":240,"completionDate":"2024-07-28"},{"nctId":"NCT06637384","phase":"PHASE4","title":"Effect of Hyaluronic Acid and Single Dose Corticosteroid Injection to Improve Wound Healing in Controlled Diabetic Patients Post Tooth Extraction.","status":"COMPLETED","sponsor":"Rimsha Rasheed","startDate":"2024-03-01","conditions":["Diabetes Mellitus","Wound Healing Delayed"],"enrollment":128,"completionDate":"2024-07-31"},{"nctId":"NCT04233164","phase":"EARLY_PHASE1","title":"Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2020-03-04","conditions":["Systemic Lupus Erythematous (SLE)"],"enrollment":47,"completionDate":"2022-05-03"},{"nctId":"NCT06497374","phase":"PHASE2","title":"FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2024-07-05","conditions":["Neuromyelitis Optica","Neuromyelitis Optica Spectrum Disorder","NMO Spectrum Disorder"],"enrollment":63,"completionDate":"2026-06-30"},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":["Pneumococcal Disease, Invasive"],"enrollment":630,"completionDate":"2026-02"},{"nctId":"NCT02798068","phase":"PHASE4","title":"Steroids and Microcirculation In Cardiac Surgery","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2016-05","conditions":["C.Surgical Procedure","Cardiac"],"enrollment":40,"completionDate":"2021-09"},{"nctId":"NCT06122987","phase":"PHASE4","title":"Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock","status":"RECRUITING","sponsor":"Kingman Regional Medical Center","startDate":"2023-12-04","conditions":["Septic Shock","Shock","Sepsis","Systemic Inflammatory Response Syndrome"],"enrollment":50,"completionDate":"2025-01"},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":["Lymphoblastic Leukemia, Acute","Lymphoblastic Leukemia, Acute, Childhood","Leukemia, Lymphoblastic, Acute, T Cell","Leukemia, Lymphoblastic, Acute"],"enrollment":6,"completionDate":"2012-01-10"},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":["Severe Acute Respiratory Syndrome"],"enrollment":70000,"completionDate":"2036-06-30"},{"nctId":"NCT06189586","phase":"NA","title":"Comparison of Aerosol Inhalation and Intravenous Glucocorticoid in the Treatment of Severe AECOPD","status":"UNKNOWN","sponsor":"Dong Yang","startDate":"2021-10-01","conditions":["Acute Exacerbation of Chronic Obstructive Pulmonary Disease"],"enrollment":100,"completionDate":"2025-07-31"},{"nctId":"NCT05698095","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers","status":"COMPLETED","sponsor":"Usona Institute","startDate":"2022-12-27","conditions":["Pharmacokinetics","Safety","Tolerability"],"enrollment":54,"completionDate":"2023-09-07"},{"nctId":"NCT06044558","phase":"","title":"Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics","status":"COMPLETED","sponsor":"LI YAN","startDate":"2022-09-01","conditions":["Kidney Transplant Patients"],"enrollment":507,"completionDate":"2023-06-01"},{"nctId":"NCT01156129","phase":"PHASE1","title":"Interventions to Decrease the Impact of Post-OPerative Ileus After Liver Transplant or Resection Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2010-09-01","conditions":["Ileus"],"enrollment":111,"completionDate":"2012-12-01"},{"nctId":"NCT05320380","phase":"PHASE1,PHASE2","title":"A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat","status":"WITHDRAWN","sponsor":"Children's Oncology Group","startDate":"2023-08-01","conditions":["Recurrent Acute Myeloid Leukemia","Recurrent B Acute Lymphoblastic Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Recurrent T Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Mixed Phenotype Acute Leukemia","Refractory T Acute Lymphoblastic Leukemia"],"enrollment":0,"completionDate":"2023-09-01"},{"nctId":"NCT01614197","phase":"PHASE1","title":"A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2015-07-03","conditions":["Lymphoblastic Leukemia, Acute, Childhood","Lymphoblastic Lymphoma","Peripheral T-cell Lymphoma"],"enrollment":16,"completionDate":"2020-09-04"},{"nctId":"NCT02798523","phase":"PHASE1","title":"Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-24","conditions":["Normal Physiology"],"enrollment":33,"completionDate":"2022-11-14"},{"nctId":"NCT05823675","phase":"PHASE1","title":"Safety and Clinical Activity of Itolizumab in aGVHD","status":"UNKNOWN","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2023-05-19","conditions":["Acute Graft Versus Host Disease"],"enrollment":44,"completionDate":"2025-02"},{"nctId":"NCT05297851","phase":"","title":"Cytoflavin in Combination With Reperfusion in Stroke Patients","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2022-04-10","conditions":["Acute Stroke"],"enrollment":200,"completionDate":"2023-03-01"},{"nctId":"NCT02977286","phase":"PHASE4","title":"Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2017-01-01","conditions":["Constipation"],"enrollment":12,"completionDate":"2019-10-09"},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":["Transplant; Failure, Kidney","EBV"],"enrollment":28,"completionDate":"2020-09"},{"nctId":"NCT04649203","phase":"PHASE3","title":"Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2020-11-25","conditions":["Diabetic Neuropathies"],"enrollment":216,"completionDate":"2021-06-06"},{"nctId":"NCT05649878","phase":"NA","title":"Evaluation of the Bioavailability of Methylprednisolone","status":"COMPLETED","sponsor":"Edda Sciutto Conde","startDate":"2021-11-05","conditions":["Methylprednisone Administration","Intranasal Administration","Intravenous Administration","Healthy Subjects"],"enrollment":8,"completionDate":"2021-11-12"},{"nctId":"NCT05177939","phase":"PHASE3","title":"Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis","status":"UNKNOWN","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2022-03-03","conditions":["Autoimmune Encephalitis"],"enrollment":40,"completionDate":"2024-10-31"},{"nctId":"NCT05580510","phase":"PHASE2,PHASE3","title":"\" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD \"","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2023-02-06","conditions":["Congenital Heart Disease","Heart Failure","Heart Failure With Reduced Ejection Fraction"],"enrollment":160,"completionDate":"2024-03-29"},{"nctId":"NCT05586295","phase":"NA","title":"Vitamin B Complex Improved Exercise Performance and Anti-fatigue","status":"COMPLETED","sponsor":"National Taiwan Sport University","startDate":"2021-03-03","conditions":["Exercise Performance","Fatigue"],"enrollment":32,"completionDate":"2021-06-26"},{"nctId":"NCT05147051","phase":"PHASE2","title":"Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2021-06-16","conditions":["Metabolic Acidosis"],"enrollment":140,"completionDate":"2022-06-22"},{"nctId":"NCT05429229","phase":"PHASE2","title":"Effect of Topical Antioxidants in Dry Eye Disease and Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Adolfo Daniel Rodriguez-Carrizalez","startDate":"2021-11-01","conditions":["Dry Eye Syndromes","Diabetic Retinopathy","Oxidative Stress","Tear Film Deficiency"],"enrollment":78,"completionDate":"2024-01-31"},{"nctId":"NCT02043587","phase":"PHASE2","title":"Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2014-01","conditions":["Acute Lymphocytic Leukemia","Adult Lymphoblastic Lymphoma"],"enrollment":31,"completionDate":"2022-04-14"},{"nctId":"NCT04377503","phase":"PHASE2","title":"Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19","status":"TERMINATED","sponsor":"Hospital Sao Domingos","startDate":"2020-05-01","conditions":["Cytokine Release Syndrome","Covid-19"],"enrollment":30,"completionDate":"2020-11-30"},{"nctId":"NCT05139849","phase":"PHASE3","title":"VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial","status":"RECRUITING","sponsor":"Tiohundra AB","startDate":"2021-11-17","conditions":["Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial"],"enrollment":1276,"completionDate":"2027-04-30"},{"nctId":"NCT04380090","phase":"PHASE2","title":"Post-Operative Constipation Following Total Knee Arthroplasty","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2020-02-21","conditions":["Constipation"],"enrollment":154,"completionDate":"2020-07-15"},{"nctId":"NCT03745664","phase":"PHASE3","title":"Corticosteroids and Myocardial Injury in CAP (COLOSSEUM TRIAL)","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2021-01-10","conditions":["Community-acquired Pneumonia"],"enrollment":122,"completionDate":"2024-09-01"},{"nctId":"NCT04343729","phase":"PHASE2","title":"Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19","status":"COMPLETED","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2020-04-18","conditions":["SARS-CoV Infection","Severe Acute Respiratory Syndrome (SARS) Pneumonia"],"enrollment":416,"completionDate":"2020-10-20"},{"nctId":"NCT04948164","phase":"PHASE3","title":"Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2018-08-01","conditions":["Migraine in Adults"],"enrollment":240,"completionDate":"2021-12-01"},{"nctId":"NCT01954056","phase":"PHASE3","title":"Hydrocortisone for Term Hypotension","status":"COMPLETED","sponsor":"NICHD Neonatal Research Network","startDate":"2014-06-19","conditions":["Infant, Newborn, Diseases","Cardiovascular Insufficiency"],"enrollment":12,"completionDate":"2018-03-20"},{"nctId":"NCT04872946","phase":"NA","title":"Topical and Oral Regimen for Skin Health","status":"COMPLETED","sponsor":"Integrative Skin Science and Research","startDate":"2019-11-26","conditions":["Skin Abnormalities"],"enrollment":74,"completionDate":"2020-05-07"},{"nctId":"NCT03509350","phase":"PHASE3","title":"Vitamin C, Thiamine, and Steroids in Sepsis","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-08-22","conditions":["Sepsis"],"enrollment":501,"completionDate":"2020-01-29"},{"nctId":"NCT03523715","phase":"PHASE4","title":"Prunes for Gastrointestinal Function After Gynecologic Surgery","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2017-11-30","conditions":["Constipation"],"enrollment":77,"completionDate":"2020-07-31"},{"nctId":"NCT03165344","phase":"NA","title":"Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Large Esophageal Carcinoma","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2017-02-10","conditions":["Esophageal Stenosis Acquired"],"enrollment":66,"completionDate":"2019-12-31"},{"nctId":"NCT04621565","phase":"NA","title":"Hydrocortisone Use During Peri-operation for Pituitary Adenomas","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-11-01","conditions":["Pituitary Adenoma","Adrenal Insufficiency","Surgery"],"enrollment":436,"completionDate":"2022-07"},{"nctId":"NCT04197115","phase":"PHASE3","title":"Vitamin C, Thiamine, Cyanocobalamine, Pyridoxine and Hydrocortisone in Sepsis","status":"COMPLETED","sponsor":"IMSS Hospital General de Zona 11, Piedras Negras","startDate":"2019-09-01","conditions":["Sepsis","Septic Shock"],"enrollment":19,"completionDate":"2020-09-30"},{"nctId":"NCT02760862","phase":"PHASE4","title":"Comparative Study Between Hydrocortisone and Mannitol in Treatment of Postdural Puncture Headache","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-10","conditions":["Headache"],"enrollment":50,"completionDate":"2015-11"},{"nctId":"NCT04499313","phase":"PHASE3","title":"Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19","status":"UNKNOWN","sponsor":"Chattogram General Hospital","startDate":"2020-08-02","conditions":["Covid19","ARDS"],"enrollment":60,"completionDate":"2020-11-30"},{"nctId":"NCT03028285","phase":"PHASE1","title":"Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy Volunteers","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2016-07-15","conditions":["Peripheral Vascular Disease"],"enrollment":48,"completionDate":"2017-01-26"},{"nctId":"NCT03800745","phase":"PHASE4","title":"Reduction of Postoperative Gastrointestinal Dysmotility Following Total Laparoscopic Hysterectomy.","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2018-11-09","conditions":["Postoperative Passage of Flatus","Postoperative Bowel Movement"],"enrollment":81,"completionDate":"2020-05-05"},{"nctId":"NCT02779283","phase":"PHASE1","title":"Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2016-01-13","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia"],"enrollment":7,"completionDate":"2018-09-20"},{"nctId":"NCT00720109","phase":"PHASE2,PHASE3","title":"Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-14","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":63,"completionDate":"2020-03-31"},{"nctId":"NCT04301479","phase":"PHASE3","title":"Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS)","status":"UNKNOWN","sponsor":"Instituto do Coracao","startDate":"2020-03","conditions":["Vasoplegia","Cardiac Surgery"],"enrollment":140,"completionDate":"2021-03"},{"nctId":"NCT03897738","phase":"NA","title":"Clinical Evaluation of Effectiveness and Safety of Amberen and Smart B in Perimenopausal Women.","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2019-04-30","conditions":["Perimenopause, Climacteric Syndrome"],"enrollment":106,"completionDate":"2020-02-18"},{"nctId":"NCT04219995","phase":"PHASE1,PHASE2","title":"Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy","status":"UNKNOWN","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2020-02-03","conditions":["Intractable Epilepsy","Convulsive Seizures"],"enrollment":10,"completionDate":"2021-02"},{"nctId":"NCT00185692","phase":"PHASE2","title":"Allogeneic Transplantation From Related Haploidentical Donors","status":"COMPLETED","sponsor":"Stanford University","startDate":"2000-08","conditions":["Blood Cancer","Leukemia","Graft Versus Host Disease","Malignancy","CLL","NHL","Hodgkin's Disease","MDS"],"enrollment":16,"completionDate":"2010-12"},{"nctId":"NCT04134403","phase":"PHASE3","title":"Steroids, Thiamine and Ascorbic Acid in Septic Shock","status":"UNKNOWN","sponsor":"Baqiyatallah Medical Sciences University","startDate":"2019-12-01","conditions":["Septic Shock"],"enrollment":80,"completionDate":"2020-12-01"},{"nctId":"NCT00568633","phase":"PHASE3","title":"Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-08","conditions":["Leukemia, Myeloid","Leukemia","Acute Myeloid Leukemia (AML)"],"enrollment":58,"completionDate":"2015-12-31"},{"nctId":"NCT00732498","phase":"PHASE2","title":"Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2006-05-15","conditions":["Lymphoma"],"enrollment":28,"completionDate":"2018-10-15"},{"nctId":"NCT03082092","phase":"PHASE4","title":"Pre-operative Intravenous Steroid in Total Knee Replacement for Pain Relief and Recovery","status":"COMPLETED","sponsor":"Queen Elizabeth Hospital, Hong Kong","startDate":"2017-06-01","conditions":["Osteoarthritis, Knee"],"enrollment":60,"completionDate":"2019-06-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular"},"_patentsChecked":true,"crossReferences":{"NDDF":"002483","VANDF":"4019582","RXNORM":"1311370","UMLSCUI":"C0142928","chemblId":"CHEMBL1200345","ChEMBL_ID":"CHEMBL1200345","PUBCHEM_CID":"9020"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1379,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 21","pmid":"41863717","title":"Pharmacodynamic evaluation and mechanism study of cord blood nucleated cell extract in the treatment of rheumatoid arthritis.","journal":"Clinical rheumatology"},{"date":"2026 Mar 21","pmid":"41863694","title":"Nitrogen metabolic characteristics and adaptive mechanisms of Paracoccus sp. QD-21 under complex nitrogenous environments.","journal":"Biodegradation"},{"date":"2026","pmid":"41836248","title":"Nanoparticle albumin-bound paclitaxel -induced severe interstitial lung disease in a gastric cancer patient: a case report.","journal":"Frontiers in oncology"},{"date":"2026 Mar 13","pmid":"41824819","title":"Impact of acupuncture combined with ganglioside therapy on serum inflammatory cytokine levels in acute cervical spinal cord injury without fracture or dislocation.","journal":"Medicine"},{"date":"2026 Mar 13","pmid":"41824219","title":"Clinical characteristics and diagnostic indicators of childhood-onset systemic lupus erythematosus complicated with macrophage activation syndrome.","journal":"Clinical rheumatology"}],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Elkins Sinn"],"status":"approved","brandName":"SODIUM SUCCINATE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1971","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1971-11-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T03:10:12.814370+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}